Literature DB >> 8431369

Breast cancer prognosis is poor when total plasminogen activator activity is low.

J Yamashita1, M Ogawa, K Inada, S Yamashita, Y Nakashima, T Saishoji, K Nomura.   

Abstract

Plasminogen activator (PA) is a serine protease which exists in two forms: tissue-type (t-PA) and urokinase-type (u-PA). The total PA activity was measured in tumour extracts of 235 breast cancer patients who were followed for a median of 8.5 years after surgery. Patients were initially divided into three groups with low (< 60 units mg-1 protein), intermediate (60-300 unit mg-1 protein), or high (> 300 unit mg-1 protein) total PA activity in tumour extracts. The PA activity was not significantly associated with the recognised prognostic factors of age, menstrual status, tumour size, lymph node involvement, histologic type, grade of anaplasia, and/or vessel involvement. A significant association was found between total PA activity and the oestrogen receptor (ER) or progesterone receptor (PgR) status. Among receptor-positive tumours, a significantly greater proportion of patients had high PA activity in their tumour extracts. Breast cancer patients with low total PA activity had a significantly shorter disease-free and overall survival rate when compared to those with intermediate or high PA activity. In univariate and multivariate analyses, total PA activity (< 60 unit mg-1 vs > or = 60 unit mg-1 protein) was found to be a significant prognostic factor for disease-free and overall survival of about the same import as lymph node involvement. Furthermore, the combination of total PA activity and nodal status could be even more precise in predicting survival times and probabilities in individual patients. This retrospective study demonstrates the total PA activity is a valuable prognostic factor in determining prognosis in human breast cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8431369      PMCID: PMC1968174          DOI: 10.1038/bjc.1993.68

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  Urokinase-type plasminogen activator antigen and early relapse in breast cancer.

Authors:  F Jänicke; M Schmitt; K Ulm; W Gössner; H Graeff
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

2.  Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade.

Authors:  P Mignatti; E Robbins; D B Rifkin
Journal:  Cell       Date:  1986-11-21       Impact factor: 41.582

3.  Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas.

Authors:  A P Sappino; N Busso; D Belin; J D Vassalli
Journal:  Cancer Res       Date:  1987-08-01       Impact factor: 12.701

4.  Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols.

Authors:  J A Foekens; H Portengen; W L van Putten; H A Peters; H L Krijnen; J Alexieva-Figusch; J G Klijn
Journal:  Cancer Res       Date:  1989-11-01       Impact factor: 12.701

5.  Estrogen regulation of human breast cancer cell line MCF-7 tissue plasminogen activator.

Authors:  H W Dickerman; H L Martinez; J I Seeger; S A Kumar
Journal:  Endocrinology       Date:  1989-07       Impact factor: 4.736

Review 6.  Do proteases play a role in cancer invasion and metastasis?

Authors:  M J Duffy
Journal:  Eur J Cancer Clin Oncol       Date:  1987-05

7.  Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.

Authors:  M J Duffy; P O'Grady; D Devaney; L O'Siorain; J J Fennelly; H J Lijnen
Journal:  Cancer       Date:  1988-08-01       Impact factor: 6.860

8.  Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells.

Authors:  R Reich; E W Thompson; Y Iwamoto; G R Martin; J R Deason; G C Fuller; R Miskin
Journal:  Cancer Res       Date:  1988-06-15       Impact factor: 12.701

9.  Tissue-type plasminogen activator, a new prognostic marker in breast cancer.

Authors:  M J Duffy; P O'Grady; D Devaney; L O'Siorain; J J Fennelly; H R Lijnen
Journal:  Cancer Res       Date:  1988-03-01       Impact factor: 12.701

10.  Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer.

Authors:  S M Thorpe; H Rochefort; M Garcia; G Freiss; I J Christensen; S Khalaf; F Paolucci; B Pau; B B Rasmussen; C Rose
Journal:  Cancer Res       Date:  1989-11-01       Impact factor: 12.701

View more
  4 in total

1.  In vitro inhibition of human malignant brain tumour cell line proliferation by anti-urokinase-type plasminogen activator monoclonal antibodies.

Authors:  M S Abaza; F A Shaban; R K Narayan; M Z Atassi
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

2.  Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer.

Authors:  J Yamashita; M Ogawa; S Yamashita; Y Nakashima; T Saishoji; K Nomura; K Inada; I Kawano
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

3.  Production of immunoreactive polymorphonuclear leucocyte elastase in human breast cancer cells: possible role of polymorphonuclear leucocyte elastase in the progression of human breast cancer.

Authors:  J I Yamashita; M Ogawa; S Ikei; H Omachi; S I Yamashita; T Saishoji; K Nomura; H Sato
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

4.  Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency.

Authors:  S Yamashita; J Yamashita; M Ogawa
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.